• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Newsletter Sign Up
Contact
  • Home
  • News
  • News
  • Regulatory Insights for Drug Master Filing (DMF) in China

Regulatory Insights for Drug Master Filing (DMF) in China

Monday, 26 July 2021 / Published in News, NMPA Registration in China, Pharmaceuticals & DMF

Regulatory Insights for Drug Master Filing (DMF) in China

Drug master filing (DMF) is a relatively recent regulatory change by China’s NMPA (National Medical Products Administration) permitting active pharmaceutical ingredients (APIs), excipients and packaging materials manufacturers better protect their intellectual property and streamline market approval. The previous system was similar to that of finished drugs and was therefore very costly and time-consuming.

Process of the drug master filing (DMF)

Starting from the preparation and submission of the application dossier to the CDE (Center for Drug Evaluation), the CDE will first check the completeness of the required documents before accepting the application. Once the application is accepted, the CDE will issue the inactive DMF number, and update the status on the online platform publicly as “I”. The CDE will then move on to the “Bundle Technical Review” process and activate the filing number upon approval. The complete process of DMF filing can be expected to take around 40 weeks in total.

Note: A pre-registration number (same as the DMF number) can be obtained before the application is accepted, however, the DMF number cannot be used by the drug manufacturer until the DMF status is updated as “I”.

Support to expect from the NMPA Legal Agent

Cisema can support overseas manufacturers to obtain DMF status “I” with the following steps:

No.Steps
1Prepare the registration form
2Obtain the pre-registration number / DMF number
3Prepare the document checklist for the application
4Check the required documents for dossier submission
5Translation of documents
6Complete the application dossier
7Submission to the NMPA
8Obtain application acceptance with DMF status “I” and prepare for “Bundle Technical Review”

Cisema can support overseas manufacturers with the “Bundle Technical Review” to obtain DMF status “A” with the following steps:

No.Steps
1Receive and Prepare the list of supplementary documents during the Bundle Technical Review
2Prepare supplementary documents with the customer together
3Check documents according to the NMPA requirements
4Dossier translation
5Prepare final supplementary dossier
6Submission dossier to NMPA
7Obtain application approval with DMF status “A”

DMF filing vs traditional registration

Before DMF was introduced in China, manufacturers could only send technical documents to individual customers / drugs manufacturers to support the registration of drugs. At present, the manufacturers can apply for their own DMF number to be used by many different drugs manufacturers in China that also allows them to have better IP protection.

NMPA Legal Agent for DMF

According to the current China NMPA (National Medical Products Administration) regulatory requirements, it is necessary to appoint an NMPA Legal Agent for DMF including the dossier submission and administrative procedures. Although the drug manufacturers can set up subsidiaries in China to take the role as their own Legal Agent or assign it to their end-product manufacturers, there are risks of over-investing or having conflict of interest for the latter.

Partnering with a well-experienced professional consulting company like Cisema has the advantages of being independent whilst using the shortest turnaround time to overcome business challenges, especially the most frequently reported problems by DMF applicants with quality standards and validation tests (batch test, safety test, long-stability test, etc.) in China.

As listed in the Q&A below, the NMPA responses to commonly asked questions by overseas manufacturers are:

Q1: Can the NMPA Legal Agent be changed?
A1: Yes.

Q2: How to change the NMPA Legal Agent?
A2: Submit a new notarized Letter of Authorization (LoA) to the NMPA.

Q3: Are there any restrictions in terms of when the NMPA Legal Agent can be changed?
A3: The NMPA Legal Agent can be changed anytime, however, the procedure must be initiated by the previous Legal Agent on the online platform for DMF filing.

By Jacky Li. Contact Cisema if you would like to learn more or receive a copy of our whitepaper on DMF in China.

Tagged under: API, DMF, Drug Master File, excipients, packaging

What you can read next

Update of Administrative Measures for the Clinical Use of Medical Devices
Technical Review Guidelines in Draft for Medical Devices Clinical Trial Data Submission
CSAR China cosmetics infringements
CSAR China cosmetics infringements lead to suspension of lavender essential oil production

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • Submission of safety information for cosmetics ingredients

    Submission of safety information for cosmetics raw materials – Draft guidelines issued

    Submission of safety information for cosmetics ...
  • avoid animal testing in Chinaweb-2023

    How to avoid animal testing in China for cosmetics | Cisema Webinar

    China’s beauty and cosmetic market has be...
  • guidelines for medical devices registration

    Guidelines for medical devices registration in China – New development plans in 2023

    Guidelines for medical devices registration in ...
  • China DMF of API

    China DMF of API, Excipient & Packaging Materials: Market & Regulatory | Cisema Webinar

    “China DMF of API, Excipient & Packag...
  • pre-phase III drug clinical trial meeting guidelines

    Pre-phase III drug clinical trial meeting guidelines released

    Pre-phase III drug clinical trial meeting guide...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP